Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT

A 62-year-old man with resected, pathology-proven small bowel neuroendocrine tumor underwent 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT to assess metastatic disease. The 111In-pentetreotide SPECT/CT scan showed no metastatic disease. Both 18F-DOPA and 68Ga-HA-DOTATATE...

Descripción completa

Detalles Bibliográficos
Autores principales: Resch, Katrin, Hung, Ryan, Abele, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250908/
https://www.ncbi.nlm.nih.gov/pubmed/35781170
http://dx.doi.org/10.1186/s41824-022-00134-5
_version_ 1784739911748812800
author Resch, Katrin
Hung, Ryan
Abele, Jonathan
author_facet Resch, Katrin
Hung, Ryan
Abele, Jonathan
author_sort Resch, Katrin
collection PubMed
description A 62-year-old man with resected, pathology-proven small bowel neuroendocrine tumor underwent 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT to assess metastatic disease. The 111In-pentetreotide SPECT/CT scan showed no metastatic disease. Both 18F-DOPA and 68Ga-HA-DOTATATE PET/CT showed hepatic and peritoneal metastatic disease. However, the burden of 18F-DOPA-avid metastatic disease was far greater compared to the burden of 68Ga-HA-DOTATATE-avid metastatic disease.
format Online
Article
Text
id pubmed-9250908
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92509082022-07-05 Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT Resch, Katrin Hung, Ryan Abele, Jonathan Eur J Hybrid Imaging Case Report A 62-year-old man with resected, pathology-proven small bowel neuroendocrine tumor underwent 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT to assess metastatic disease. The 111In-pentetreotide SPECT/CT scan showed no metastatic disease. Both 18F-DOPA and 68Ga-HA-DOTATATE PET/CT showed hepatic and peritoneal metastatic disease. However, the burden of 18F-DOPA-avid metastatic disease was far greater compared to the burden of 68Ga-HA-DOTATATE-avid metastatic disease. Springer International Publishing 2022-07-04 /pmc/articles/PMC9250908/ /pubmed/35781170 http://dx.doi.org/10.1186/s41824-022-00134-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Resch, Katrin
Hung, Ryan
Abele, Jonathan
Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
title Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
title_full Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
title_fullStr Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
title_full_unstemmed Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
title_short Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
title_sort gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111in-pentetreotide spect/ct, 18f-dopa pet/ct and 68ga-ha-dotatate pet/ct
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250908/
https://www.ncbi.nlm.nih.gov/pubmed/35781170
http://dx.doi.org/10.1186/s41824-022-00134-5
work_keys_str_mv AT reschkatrin gastrointestinalneuroendocrinetumorwithdiscordantmetastaticdiseaseon111inpentetreotidespectct18fdopapetctand68gahadotatatepetct
AT hungryan gastrointestinalneuroendocrinetumorwithdiscordantmetastaticdiseaseon111inpentetreotidespectct18fdopapetctand68gahadotatatepetct
AT abelejonathan gastrointestinalneuroendocrinetumorwithdiscordantmetastaticdiseaseon111inpentetreotidespectct18fdopapetctand68gahadotatatepetct

Ejemplares similares